Between legal challenges and practical implementation problems, President Trump isn’t leaving much policy for the Biden team to work with. But he did shift the drug-policy conversation.
You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.
